VIA Pharmaceuticals (VIA Pharmaceuticals) GF Score : 0/100 (As of Jun. 21, 2024)

View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals GF Score?

VIA Pharmaceuticals has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes VIA Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

VIA Pharmaceuticals (GREY:VIAP) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

VIA Pharmaceuticals GF Score Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

750 Battery Street, Suite 330, San Francisco, CA, USA, 94111

Website

http://www.baycitycapital.com

VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.

Executives

Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p.	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp	10 percent owner	750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright	officer: V.P. ? Finance, Controller	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen	director, officer: CEO and President	750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson	director	14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub	officer: SVP, Research & Development	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun	officer: Chief Medical Officer	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd	10 percent owner, other: Possible Member of 10% Group	BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-12-2009

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009